Devanand Patil
Herceptin Biosimilar Market: Introduction
Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used to treat patients suffering from HER2+ve breast cancer and gastric cancers. It is primarily administered intravenously in cancer patients. Herceptin binds to HER2 receptors on the surface of breast cancer cells and blocks them from receiving growth signals, thereby leading to apoptosis and decrease in mutation of cells.
Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82800
Key Drivers and Restraints of Global Herceptin Biosimilar Market
- Breast cancer is one of the leading causes of death among women across the globe. Increase in incidence and prevalence of gastric & breast cancer among people, especially women, is a key factor boosting the growth of the global Herceptin biosimilar market. According to a report by the World Health Organization in 2019, nearly 627,000 women across the globe succumbed to breast cancer, which accounted for around 15% of all cancer deaths among women, in 2018.
- New product launches along with a number of products in pipeline for clinical trials, approval of new Herceptin biosimilar drugs by key companies, technological advancements, increase in health care expenditure, and considerable research & development activities drive the global Herceptin biosimilar market.
- However, lack of awareness among people about the treatment of gastric & breast cancer with Herceptin is likely to hamper the growth of the global Herceptin biosimilar market in the next few years
Request COVID Analysis on Herceptin Biosimilar Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82800
Breast Cancer to Dominate Global Herceptin Biosimilar Market
- In terms of indication, the global Herceptin biosimilar market can be classified into breast cancer, gastric cancer, and others
- The breast cancer segment is projected to dominate the global Herceptin biosimilar market during the forecast period due to increase in incidence and prevalence rate of breast cancer among women
Hospital Pharmacy Segment to Capture Largest Market Share
- Based on distribution channel, the global Herceptin biosimilar market can be divided into hospital pharmacies, retail pharmacies, online pharmacies, oncology centers, and others
- The hospital pharmacies segment is anticipated to capture the largest market share due to rise in the number of patients admitted to hospitals & clinics for treatment and health care infrastructure provided by hospitals such as intensive care units (ICU) and ventilators.
North America to Lead Global Herceptin Biosimilar Market
- In terms of region, the global Herceptin biosimilar market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America accounted for the largest market of the global Herceptin biosimilar market in 2020, followed by Europe. Increase in number of people suffering from gastric & breast cancer, technological advancements, rise in government grants & funding, and presence of large number of key players boost the growth of the market in North America.
Pre Book Herceptin Biosimilar Market Report- https://www.transparencymarketresearch.com/checkout.php?rep_id=82800<ype=S
Key Manufacturers Operating in Global Herceptin Biosimilar Market
The global Herceptin biosimilar market was highly fragmented in 2020. Key manufacturers operating in the global market are:
- Amgen, Inc.
- AryoGen Biopharma
- Biocon Limited
- Celltrion, Inc.
- Pfizer, Inc.
- Merck & Co., Inc.
- Accord Healthcare Ltd.
- Gedeon Richter plc
- Genor Biopharma Company Ltd.
- Mabion SA
- Mylan N.V
- Roche Holding AG
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
0
Devanand Patil
Related Articles
It is a targeted therapy that is designed to block the action of a protein called HER2/neu. This protein is found in high levels in about 20% of breast cancer patients, and its overexpression is associated with a more aggressive form of the disease. Therefore, Herceptin Biosimilar manufacturers must invest in extensive education and awareness programs to increase trust and confidence in their products. Unlike generic drugs, which are approved based on bioequivalence studies, biosimilars require extensive comparative data between the biosimilar and the reference product. Herceptin biosimilars offer a more affordable option for patients with HER2-positive breast cancer, improving access to life-saving treatmentsRead More @ https://cmibloginsight.
0
According to the recent report by IMARC Group, entitled “Biosimilar Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2023-2028”, the global biosimilar market size reached US$ 16. To be labeled as a biosimilar, a biological drug must be proved similar in terms of efficacy, safety, and quality. com/biosimilar-market/requestsample Biosimilar Market Trends:The surging prevalence of chronic diseases, such as cancer and autoimmune diseases, especially among the geriatric population, represents one of the key factors significantly contributing to the market growth. type=report&id=497&flag=CKey Highlights of the Report: Market Performance (2017-2022)Market Outlook (2023-2028)Market TrendsMarket Drivers and Success FactorsImpact of COVID-19Value Chain AnalysisComprehensive mapping of the competitive landscapeIf you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization. About Us IMARC Group is a leading market research company that offers management strategy and market research worldwide.
0
The research provides an overview of the worldwide Biosimilar market, including market characteristics, market segmentation analysis, market size, customer landscape, and geographical landscape. com/request-sample/83592 Biosimilar Market Key Players:It then discusses the top competitors in the worldwide Biosimilar market, as well as emerging players, in detail, including market share based on revenue, demand, high-quality product makers, sales, and service providers. Key Questions Answered in the Biosimilar Market Report are: Which are the major companies in the Biosimilar market? Which region holds the largest market share in the Biosimilar market? What factors are anticipated to drive the Biosimilar market?
0
The Biosimilar Interleukins Global Market Report 2021-31 by The Business Research Company describes and explains the global biosimilar interleukins market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region. The biosimilar interleukins market share is expected to reach $7. id=3433&type=smp Biosimilar Interleukins Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
0
Learn More On The Remicade Biosimilar Market:https://www. The remicade biosimilar market size is expected to see exponential growth in the next few years. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence. The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market.
0
The Biosimilar Interleukins Global Market Report 2023, provides comprehensive information on the biosimilar interleukins market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. id=3433&type=smp The biosimilar interleukins market is segmented: 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes North America was the largest region in the biosimilar interleukins market in 2022. Africa Biosimilar Interleukins Market 27. Key Mergers And Acquisitions In The Biosimilar Interleukins Market 29. Appendix Read Related Reports https://www.
0
